GeneDx Holdings (WGS) Operating Leases (2022 - 2026)

GeneDx Holdings (WGS) has reported Operating Leases for 5 consecutive years, with $66.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases rose 10.7% year-over-year to $66.3 million; the TTM figure through Mar 2026 stood at $66.3 million (up 10.7% YoY), while the FY2025 annual figure was $56.0 million, down 8.0% from the prior year.
• Operating Leases rose to $66.3 million in Q1 2026 per WGS's latest filing, from $56.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $69.1 million in Q2 2023 and bottomed at $56.0 million in Q4 2025.
• Historically, Operating Leases has averaged $63.4 million across 5 years, with a median of $63.4 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Leases slipped 12.0% — and 2026, when it rose 10.7%.
• GeneDx Holdings' Operating Leases stood at $66.1 million in 2022, then gained by 0.68% to $66.6 million in 2023, then fell by 8.51% to $60.9 million in 2024, then fell by 8.0% to $56.0 million in 2025, then advanced by 18.35% to $66.3 million in 2026.
• Business Quant data shows WGS's Operating Leases at $66.3 million in Q1 2026, $56.0 million in Q4 2025, and $57.2 million in Q3 2025.